<?xml version="1.0" encoding="UTF-8"?>
<p>In the maintenance phase there was a small significant difference in favour of observation only for Global Health Status/Quality of Life at 3 months with a persistent trend for detriment at 6 months and 12 months (Global Health Status/Quality of Life lower with thalidomide maintenance, 3 months: −3·39 [95% CI −6·33, −0·45], 
 <italic>P</italic> = 0·02; 6 months: −1·28 [95% CI −4·86, 2·30], 
 <italic>P</italic> = 0·48; 12 months: −2·15 [95% CI −5·98, 1·67], 
 <italic>P</italic> = 0·27, Fig 
 <xref rid="bjh15459-fig-0002" ref-type="fig">2</xref>C). There were no significant differences for Pain, Fatigue or Physical Functioning (Fig 
 <xref rid="bjh15459-fig-0002" ref-type="fig">2</xref>C).
</p>
